| 前收盘价格 | 10.69 |
| 收盘价格 | 10.70 |
| 成交量 | 2,138,443 |
| 平均成交量 (3个月) | 5,022,901 |
| 市值 | 1,789,020,544 |
| 市盈率 (P/E TTM) | 4.26 |
| 价格/销量 (P/S) | 1.65 |
| 股市价格/股市净资产 (P/B) | 33.20 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业毛利率 | 38.14% |
| 营业利益率 (TTM) | 77.40% |
| 稀释每股收益 (EPS TTM) | 2.75 |
| 季度收入增长率 (YOY) | 610.30% |
| 季度盈利增长率 (YOY) | 179.90% |
| 流动比率 (MRQ) | 2.06 |
| 营业现金流 (OCF TTM) | -189.21 M |
| 杠杆自由现金流 (LFCF TTM) | 61.88 M |
| 资产报酬率 (ROA TTM) | 19.97% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Novavax, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
-0.1
| 分析师共识 | 3.0 |
| 内部交易活动 | -5.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.10 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 8.78% |
| 机构持股比例 | 57.19% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Shah Capital Management | 31 Dec 2025 | 14,558,780 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 19.00 (BTIG, 73.04%) | 购买 |
| 中 | 17.50 (59.38%) | |
| 低 | 16.00 (HC Wainwright & Co., 45.72%) | 购买 |
| 平均值 | 17.50 (59.38%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 9.17 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 16.00 (45.72%) | 购买 | 10.14 |
| BTIG | 20 Jan 2026 | 19.00 (73.04%) | 购买 | 8.20 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CASEY MARK J | - | 9.82 | -12,592 | -120,287 |
| DRAGHIA-AKLI RUXANDRA | - | 9.49 | -11,313 | -107,360 |
| JACOBS JOHN C | - | 9.82 | -107,738 | -1,047,426 |
| KELLY JAMES PATRICK | - | 9.87 | -55,120 | -544,420 |
| O'HARA ELAINE | - | 9.82 | -38,773 | -378,579 |
| 累积净数量 | -225,536 | |||
| 累积净值 ($) | -2,198,073 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 9.80 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KELLY JAMES PATRICK | 职员 | 07 Mar 2026 | 处理 (-) | 5,904 | 9.98 | 58,922 |
| KELLY JAMES PATRICK | 职员 | 07 Mar 2026 | 执行期权 | 12,223 | - | - |
| DRAGHIA-AKLI RUXANDRA | 职员 | 03 Mar 2026 | 处理 (-) | 11,313 | 9.49 | 107,360 |
| DRAGHIA-AKLI RUXANDRA | 职员 | 03 Mar 2026 | 执行期权 | 26,667 | - | - |
| CASEY MARK J | 职员 | 03 Mar 2026 | 处理 (-) | 11,378 | 9.49 | 107,977 |
| CASEY MARK J | 职员 | 03 Mar 2026 | 执行期权 | 37,500 | - | - |
| O'HARA ELAINE | 职员 | 03 Mar 2026 | 处理 (-) | 22,429 | 9.49 | 212,851 |
| O'HARA ELAINE | 职员 | 03 Mar 2026 | 执行期权 | 56,334 | - | - |
| KELLY JAMES PATRICK | 职员 | 03 Mar 2026 | 处理 (-) | 20,850 | 9.49 | 197,867 |
| KELLY JAMES PATRICK | 职员 | 03 Mar 2026 | 执行期权 | 43,167 | - | - |
| JACOBS JOHN C | 职员 | 03 Mar 2026 | 处理 (-) | 69,288 | 9.49 | 657,543 |
| JACOBS JOHN C | 职员 | 03 Mar 2026 | 执行期权 | 150,167 | - | - |
| CASEY MARK J | 职员 | 01 Mar 2026 | 处理 (-) | 1,214 | 10.14 | 12,310 |
| CASEY MARK J | 职员 | 01 Mar 2026 | 执行期权 | 4,000 | - | - |
| O'HARA ELAINE | 职员 | 01 Mar 2026 | 处理 (-) | 16,344 | 10.14 | 165,728 |
| O'HARA ELAINE | 职员 | 01 Mar 2026 | 执行期权 | 59,600 | - | - |
| KELLY JAMES PATRICK | 职员 | 01 Mar 2026 | 处理 (-) | 28,366 | 10.14 | 287,631 |
| KELLY JAMES PATRICK | 职员 | 01 Mar 2026 | 执行期权 | 58,666 | - | - |
| JACOBS JOHN C | 职员 | 01 Mar 2026 | 处理 (-) | 38,450 | 10.14 | 389,883 |
| JACOBS JOHN C | 职员 | 01 Mar 2026 | 执行期权 | 83,333 | - | - |
| 显示更多 | ||||||
| 日期 | 类型 | 细节 |
|---|---|---|
| 20 Jan 2026 | 公告 | Novavax Announces Entering into a License Agreement with Pfizer |
| 07 Jan 2026 | 公告 | Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合